Zepbound Half-Life and Pharmacokinetics, Straight From the FDA Label

This is a reference page. Its job is to reproduce, accurately and with attribution, the pharmacokinetic statements in the FDA-approved United States prescribing information for Zepbound, so somebody keeping a personal medication record can see where the numbers originate.

It is not medical advice. It has not been written or reviewed by a clinician, and it makes no recommendation about whether any medication is appropriate for anybody. It does not tell you how much to take, when to take it, or when to change anything.

If you want guidance rather than reference material, the right next step is your prescriber or pharmacist, not a page like this one.

All figures on this page come from one document: ZEPBOUND (tirzepatide) injection, for subcutaneous use — the United States Prescribing Information approved by the FDA, read on DailyMed accessed 1 September 2026. The label records an Initial U.S. Approval of 2022.

Section 1 gives two indications: in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long-term in adults with obesity or overweight with at least one weight-related comorbid condition; and to treat moderate to severe obstructive sleep apnea in adults with obesity.

The pharmacokinetic statements sit in Section 12.3. Labels are revised, which is why the access date is printed beside each figure rather than buried in a footer. If a number here ever conflicts with the current label, the current label wins.

Zepbound and Mounjaro are both tirzepatide, and a reader who checks both pages will notice the half-life statements are not identical. Mounjaro's label says approximately 5 days; Zepbound's says approximately 5-6 days in patients with overweight or obesity, and in patients with obstructive sleep apnea and obesity.

This is not a contradiction and it is not an error in either document. The two products are studied in different populations for different indications, and the pharmacokinetic sections report what was observed in those populations. A label is a description of a specific evidence base, not a universal constant.

It is also a good argument for how this pillar is built. A reference page that quoted "tirzepatide half-life" as a single number would have to silently pick one label over the other. Quoting the specific document, with its section and access date, preserves a real distinction that a tidier presentation would erase.

Section 12.3 states a mean absolute bioavailability of 80% following subcutaneous administration, matching the figure on the Mounjaro label. Absolute bioavailability is the fraction of an administered dose reaching systemic circulation unchanged, and eighty percent is high, as is typical for a subcutaneous peptide.

On timing, this label is more informative than most: it states that the median time to maximum plasma concentration is 24 hours, within a range of 8 to 72 hours.

That distinction is worth dwelling on. Elsewhere in this pillar, pages warn that a precise time-to-peak figure is usually somebody's midpoint of a labeled range. Here it is not — 24 hours is the median the label itself reports. When a reference table quotes 24 hours for tirzepatide it happens to be quoting a labeled value, though the wide range around it still means the figure describes a population rather than a person.

The label states that steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once-weekly administration.

Because the weekly dosing interval is only a little longer than one half-life, each dose arrives while a meaningful proportion of the previous one is still present, and levels build across roughly the first month before flattening. This is ordinary pharmacology for any medication dosed at an interval comparable to its half-life, and it is what the four-week steady-state statement describes.

For record-keeping the consequence is the one that recurs throughout this pillar: a given week is not an isolated event. What somebody experiences reflects an accumulated level several weeks contributed to, which is exactly why a continuous record is more useful to a clinician than a recollection of one bad day.

Zepbound is escalated gradually rather than started at a maintenance level, and the prescribing information describes that escalation in its dosage and administration section.

This page does not reproduce it — not the steps, not the intervals, not the conditions for moving between them. The information is public, but a titration schedule is only meaningful attached to a specific person, and a page that publishes one hands readers a plan nobody qualified has given them. Escalation timing is individualised for tolerability, for other medications, and for clinical circumstances a website cannot see.

A stepwise schedule exists. It is in the label. It is applied to you by your prescriber. A tracking app's role starts afterwards, when there is something real to record.

GLP-1 Tracker records what you enter: the date of each dose you log, the injection site you noted, weight and BMI entries added over time, meals captured through the photo scan with calories, protein and fiber estimated, and notes about how a week went.

It holds those in one timeline rather than scattered across a notes app, a paper diary and memory. For a medication with two possible indications, that continuity is worth something specific: the thing a clinician usually wants to know is what changed and when, and a record answers that in a way recollection does not.

What the app does not do is decide anything. It does not evaluate whether your routine is working, it does not flag anything as clinically significant, and it does not generate schedules.

GLP-1 Tracker includes an educational medication-level view that draws a curve from logged doses and a published half-life figure of the kind quoted on this page.

It is a teaching illustration built from population-level label figures, not from you. It cannot account for your body weight, your kidney function, injection-site variation, adherence gaps, or ordinary biological variability. And note that even the label's own timing figure carries a range from 8 to 72 hours around its 24-hour median, so a smooth curve is smoothing over a great deal.

The legitimate use is intuition: seeing why a weekly medication accumulates over the first month, or why a missed dose does not produce an immediate cliff. The illegitimate use is treating it as information about your own body, or letting it influence a dose. It should never do either.